GO
Loading...

Biogen Idec Inc

More

  • Okay, the real "Granddaddy of 'em all" was actually this past Tuesday at the Rose Bowl (I promise that's my last reference to the amazing USC Trojans unless they win a split national championship), but the granddaddy of healthcare investment conferences begins on Monday in San Francisco.

  • Healthy Returns? Friday, 4 Jan 2008 | 6:51 PM ET

    What's the trade heading into next week's JPMorgan Healthcare Conference?

  • My 7 For '07: The Pharma Year in Review Friday, 28 Dec 2007 | 1:57 PM ET

    The seven biggest stories in my sectors in 2007? Avandia, Dendreon, Pfizer, Biogen were just a few of the topics that made this a fascinating year for the pharmaceuticals and biotechnology industries.

  • Your First Move For Monday Dec. 17th Friday, 14 Dec 2007 | 7:22 PM ET

    Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!

  • The Fast Money Misfires Friday, 14 Dec 2007 | 6:55 PM ET

    Sometimes a stock is hot and other time it just burns. Following are the Fast Money misfires.

  • Novartis Cuts, While Biogen Idec Cuts And Runs Thursday, 13 Dec 2007 | 4:06 PM ET
    Novartis

    Novartis is the latest company to brand its downsizing, cost-cutting campaign. The Swiss drugmaker is calling its initiative, "Forward". It's not an acronym. So, "Forward" means Novartis is going to try to save $1.6 billion in 2010 and get rid of 2,500 employees. Although I don't think "Forward" is the word which begins with "f" that the affected workers would use to describe the initiative.

  • Stocks Close Mixed As Dow Rebounds Thursday, 13 Dec 2007 | 3:59 PM ET

    Stocks closed mixed as worries about a weakening economy and credit crunch continued to rattle the markets.

  • Biogen Idec Gets No Takeover Bids; Stock Plummets Wednesday, 12 Dec 2007 | 5:05 PM ET
    Carl Icahn

    Biogen Idec said after markets closed Wednesday that it ended its review of strategic options after failing to receive any definitive takeover bids.

  • Dick Clark (Merck CEO) Still Rolling Out Hits For Analysts Wednesday, 12 Dec 2007 | 12:13 PM ET

    The morning after the Merck annual business briefing, the analyst reviews are pouring in. For the most part, the ones that I've received at least, say it had a good beat. Only Sanford C. Bernstein's Tim Anderson says he can't dance to it. He titles a research note to clients, "Annual Business Review Uneventful--No Real Surprises, Positive Or Negative."

  • Pfizer's Smoking Problem Helps "Suffocate" Stock Price Wednesday, 21 Nov 2007 | 11:27 AM ET

    Late yesterday afternoon, the Food and Drug Administration put out what it calls an "Early Communication" announcing that it's looking into possible dangerous side effects from Pfizer's hot, new smoking cessation pill, Chantix. The company sold nearly a quarter-billion dollars worth of the drug in the third quarter which put it on track to quickly achieve billion-dollar blockbuster status.

  • Crazy As 100 Squirrels In A Bag Tuesday, 20 Nov 2007 | 6:39 PM ET

    What are the best trades when a volatile market acts like 100 squirrels in a bag?

  • Amgen: Is There A Takeout Scenario? Wednesday, 24 Oct 2007 | 1:15 PM ET

    On a day when the markets are selling off, shares of the world's biggest biotech company--by sales--are holding their own. There are a few things that could be buoying Amgen's stock. The company won a huge patent battle yesterday, it reports earnings after the closing bell today and an analyst has upgraded the stock to "Outperform".

  • Glaxo's Avandia Nose Dive: What It Means Wednesday, 24 Oct 2007 | 11:48 AM ET

    Shares in the world's second biggest drug company, GlaxoSmithKline, are giving back all of yesterday's gains in early trading this morning. That's because sales of its embattled diabetes drug, Avandia and other Avandia-related products took a huge dive in the third quarter. Down 48% in the U.S. from the same time last year.

  • Biogen Idec Earnings A 'Huge Swing and a Miss' Tuesday, 23 Oct 2007 | 12:13 PM ET

    Biotech giant Biogen Idec posted some disappointing third-quarter results, falling short of Wall Street expectations across the board. Does it matter, since the company has announced it's up for sale? Biotech analyst Christopher Raymond of Robert W. Baird thinks it does.

  • Biogen Earnings Fall Short of Analysts' Targets Tuesday, 23 Oct 2007 | 9:51 AM ET

    Biotechnology company Biogen Idec, which put itself up for sale earlier this month, reported third-quarter earnings and revenue Tuesday that fell short of analysts' expectations.

  • Safety After Sudden Sell-Off Monday, 22 Oct 2007 | 11:41 AM ET

    Will Friday’s sell-off have a dramtaic impact on Monday's trading and the earnings flood that lies ahead?

  • Drug Earnings Deluge Thursday, 18 Oct 2007 | 7:01 PM ET

    The Big Pharma earnings season is in full swing with Pfizer (PFE), Eli Lilly (LLY) and Wyeth (WYE) out Thursday and Merck (MRK) and Schering-Plough (SGP) reporting Monday. What’s the trade as the drug companies deal with their ailing pipelines?

  • Mad Mail: Buy, Sell or Hold Biogen? Tuesday, 16 Oct 2007 | 10:31 AM ET

    Also, explaining the short interest in Hologic and the "mindboggling" run in PetroChina.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Dow Ends Below 14,000 as Financial Stocks Slump Monday, 15 Oct 2007 | 4:00 PM ET

    Stocks closed lower after financial giant Citigroup halted its stock buyback plan and said it and two other big U.S. banks will create a multibillion-dollar fund in order to support the struggling commercial debt market.

  • Biogen Idec: First Of A Biotech Buying Binge? Monday, 15 Oct 2007 | 12:52 PM ET

    For quite some time now analysts and investors have been speculating that big pharma would go on a biotech buying binge. So, will the announcement by Biogen Idec late Friday that it's putting itself on the market be the spark that ignites an M & A explosion in the sector? Perhaps.

Most Popular Video

Wednesday, 23 Apr 2014 | 12:32 AM ET

Eddie Tam, CIO at Central Asset Investments, says China will see a slowdown for a long time as a trade-off for avoiding a hard landing in its economy.

Tuesday, 22 Apr 2014 | 10:48 PM ET

Todd Elmer, Currency Strategist at Citi, discusses whether the currency's sharp drop following weaker-than-expected quarterly inflation data was justified.

Tuesday, 22 Apr 2014 | 10:30 PM ET

Adaire Fox-Martin, COO, Asia Pacific Japan at SAP, elaborates on the firm's "stunning results" in Southeast Asia, India and the sector of cloud computing in the first-quarter.